RAPT Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q3 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
RAPT Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2018 to Q2 2024.
  • RAPT Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$29.3M, a 3.41% decline year-over-year.
  • RAPT Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$129M, a 21.6% decline year-over-year.
  • RAPT Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$127M, a 48.1% decline from 2022.
  • RAPT Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$85.8M, a 24% decline from 2021.
  • RAPT Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$69.2M, a 30.1% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$129M -$29.3M -$966K -3.41% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$128M -$32.5M -$956K -3.03% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$127M -$33.2M -$8.79M -36% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$118M -$33.9M -$12.2M -56.5% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$106M -$28.4M -$9.46M -50% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$96.6M -$31.6M -$10.8M -51.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$85.8M -$24.4M -$6.4M -35.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 -$79.4M -$21.7M -$3.15M -17% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$76.3M -$18.9M -$2.83M -17.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 -$73.4M -$20.8M -$4.22M -25.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$69.2M -$18M -$4.95M -37.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-14
Q3 2021 -$64.3M -$18.5M -$3.95M -27.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$60.3M -$16.1M -$3.57M -28.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 -$56.7M -$16.6M -$3.52M -27% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-11
Q4 2020 -$53.2M -$13.1M -$274K -2.14% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 -$52.9M -$14.6M -$4.27M -41.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$48.7M -$12.5M -$1.55M -14.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 -$47.1M -$13M -$3.49M -36.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q4 2019 -$43.6M -$12.8M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-11
Q3 2019 -$10.3M +$230K +2.18% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$11M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 -$9.54M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q3 2018 -$10.5M Jul 1, 2018 Sep 30, 2018 10-Q 2019-12-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.